Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 203,070 | 163,914 | 110,248 | 49,590 | 20,435 |
| Cost of Goods | 36,832 | 28,645 | 22,634 | 13,318 | 9,328 |
| Gross Profit | 166,238 | 135,269 | 87,614 | 36,272 | 11,107 |
| Operating Expenses | 200,716 | 179,924 | 170,188 | 151,746 | 94,981 |
| Operating Income | -33,646 | -44,010 | -81,940 | -115,156 | -83,546 |
| Interest Expense | 30,485 | 26,609 | 14,102 | 7,180 | 10,660 |
| Other Income | 7,027 | 7,115 | -42 | -389 | 2,956 |
| Pre-tax Income | -57,104 | -63,504 | -96,084 | -122,725 | -91,250 |
| Income Tax | -2,268 | -1,249 | -1,424 | N/A | -110 |
| Net Income Continuous | -54,836 | -62,255 | -94,660 | -122,725 | -91,140 |
| Net Income | $-54,836 | $-62,255 | $-94,660 | $-122,725 | $-91,140 |
| EPS Basic Total Ops | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 |
| EPS Basic Continuous Ops | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 |
| EPS Diluted Total Ops | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 |
| EPS Diluted Continuous Ops | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 |
| EPS Diluted Before Non-Recurring Items | -0.33 | -0.45 | -0.68 | -1.54 | -2.14 |
| EBITDA(a) | $-18,014 | $-28,645 | $-67,713 | $-112,316 | $-81,099 |